Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034

Executive Summary

Country Wise- Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Epidemiology

Estimates show the highest Incident population of EGFR-NSCLC is in the United States. Furthermore, among the European 5 countries, the Germany had highest incident population of NSCLC.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Drug Chapters

Drug chapter segment of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer report encloses the detailed analysis of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Marketed Drugs

Iressa (gefitinib): AstraZeneca
In July 2015, the US FDA approved Iressa (gefitinib) for the first-line treatment of patients with NSCLC whose tumor harbor specific types of EGFR gene mutations, as detected by an FDA-approved test. However, before a nod from the US FDA, in July 2009, European Medicines Agency (EMA) granted marketing authorization for gefitinib for the treatment of locally advanced or metastatic NSCLC with sensitizing mutations of the EGFR gene, across all lines of therapy.

Tagrisso (Osimertinib): AstraZeneca
Tagrisso (Osimertinib) has been approved for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. For the previously untreated EGFR mutation-positive metastatic NSCLC, it was demonstrated in a randomized, multicenter, double-blind, active-controlled trial (FLAURA [NCT02296125]). The use of osimertinib in the frontline setting had increased quite rapidly in the few months after the FLAURA data were released, and was expected to continue for a while.

Products detail in the report.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Emerging Drugs

TAK-788 (AP32788): Takeda
Takeda is investigating their drug candidate, TAK-788 (AP32788), which is a potent and selective next-generation, small-molecule tyrosine kinase inhibitor (TKI) intelligently designed and under clinical investigation to inhibit EGFR and human EGFR 2 (HER2) exon 20 mutations with selectivity over wild type (WT) EGFR. It is currently being explored in EGFR exon 20 insertion mutations in several clinical trials. Previously conducted non-clinical studies demonstrated antitumor activity against de novo mutations in EGFR including EGFR exon 20 insertions and the acquired resistance mutation T790M. Last year, Takeda presented the result of phase I/II trial, and results from this trial showed that TAK-788 effectively treated NSCLC patients whose tumor harbor EGFR exon 20 insertion mutations and who had been previously treated with multiple prior therapies.

Lazertinib: Yuhan Corporation/ Janssen Research & Development
It is a third-generation EGFR- tyrosine kinase (EGFR-TK) inhibitor that could penetrate the brain barrier. Yuhan believes that it has the potential to be first-line therapy for treatment of NSCLC. Lazertinib is currently undergoing Phase III trials in Korea. Interim data has shown that Lazertinib exhibited robust disease activity in patients with NSCLC with acquired resistance to EGFR-TKIs, with or without brain metastasis and was well-tolerated with low rates of Grade 3 or higher adverse events. The South Korean firm entered into licensing deal with Janssen for Lazertinib. Under this agreement, Janssen will be responsible for the development of Lazertinib. In addition to this, Janssen will also be responsible for the manufacturing and commercialization of this drug except for Korea. Both companies under this collaboration initiated Phase I/II clinical trial outside Korea.

JNJ-61186372 (JNJ-6372): Janssen
Janssen, a Johnson and Johnson Company is currently investigating their lead product JNJ-61186372 (JNJ-6372) in Advance NSCLC patients. It is a novel Human Bispecific EGFR and c-Met Antibody that company believes has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies. These two receptors (EGFR and c-Met), in their mutant form, play major roles in the proliferation of cancer cells. By targeting EGFR and c-Met, JNJ-61186372 triggers a chain of events leading to the degradation of these receptors and prevents their activation in the future. The mechanism of JNJ-61186372 is believed to prevent the proliferation of tumor cells and thus aids in the treatment of cancer.

Products detail in the report.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

Key Findings

According to the publisher, Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer in seven major markets was found to be USD 1,893 million in 2017 which is expected to increase during study period (2017-2030).

The United States Market Outlook

In 2017, the total market size of EGFR-NSCLC therapies was found to be USD 1,150 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of EGFR-NSCLC therapies was found to be USD 536 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of EGFR-NSCLC therapies in Japan was found to be USD 208 million in 2017.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Pipeline Development Activities

The drugs which are in pipeline includes:
1. JNJ-61186372 (JNJ-6372): Janssen Research & Development
2. Lazertinib: Yuhan Corporation/ Janssen Research & Development
3. TAK-788: Takeda
and others….

Products detail in the report.

Pipeline Development Activities

Key Points

1. In March 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced stated that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 for the treatment of patients with metastatic NSCLC with EGFR Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Drugs Uptake

The EGFR NSCLC market is expected to be dominated by Tagrisso (osimertinib). The market domination is mainly because of it selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations, also its use as first-line therapy in NSCLC does not lead to T790M mutations. Other therapies like JNJ-6372 and TAK-788 which are mainly targeting EGFR exon 20 insertion mutations are expected to generate revenue mainly attributed due to lack of treatment options for EGFR exon 20 insertion mutations.

Access and Reimbursement Scenario in Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Therapies

• In January 2020, the National Institute for Health and Care Excellence (NICE) has published final guidance. And as per that guidance, NICE does not recommend AstraZeneca’s Tagrisso for untreated locally advanced or metastatic EGFR-positive NSCLC. This decision was entirely based on a clinical trial, which despite showing that the drug stalled cancer-growth for around 18.9 months compared with 10.2 months in patients treated with erlotinib or gefitinib, did not show direct evidence that the drug would be more effective than afatinib, which may be more effective than erlotinib or gefitinib. As it stands, the first line of treatment for locally advanced stages of NSCLC is a daily oral dose of afatinib, erlotinib, gefitinib or dacomitinib, which have all previously been recommended by NICE. Unfortunately, the drug is not considered eligible for inclusion in the Cancer Drugs Fund (CDF) as it does not have the potential to be cost-effective at the price offered

KOL - Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.

Report Highlights

• In the coming years, Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer. Launch of emerging therapies, will significantly impact the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Report Insights

• Patient Population
• Therapeutic Approaches
• Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Pipeline Analysis
• Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Report Key Strengths

• 11 Years Forecast
• 7MM Coverage

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Epidemiology Segmentation

• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Report Assessment

• SWOT Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Conjoint Analysis
• Market Attractiveness
• Market Drivers and Barriers

Key Questions Answered

Market Insights:

• What was the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer total market Size as well as market size by therapies across the 7MM during the study period (2017-2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market size during the study period (2017-2030)?
• At what CAGR, the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market is expected to grow in 7MM during the study period (2017-2030)?
• What would be the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market outlook across the 7MM during the study period (2017-2030)?
• What would be the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
• Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
• Among the emerging therapies, what are the potential therapies which are expected to disrupt the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer?
• What is the historical Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What would be the forecasted patient pool of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer?
• Out of all the 7MM countries, which country would have the highest Incident population of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer during the study period (2017-2030)?
• At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the treatment of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer along with the approved therapy?
• What are the current treatment guidelines for the treatment of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer in the US, Europe and Japan?
• What are the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer?
• How many therapies are developed by each company for the treatment of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer?
• How many emerging therapies are in mid stage, and late stage of development for the treatment of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer and their status?
• What are the key designations that have been granted for the emerging therapies for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer?
• What are the global historical and forecasted market of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.
• To understand the future market competition in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.
• To understand the future market competition in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.

• AstraZeneca
• Pfizer
• Novartis Pharmaceuticals
• Janssen Research & Development
• Yuhan Corporation/ Janssen Research & Development
• Takeda